was successfully added to your cart.

Have you won a prize in the IDDT Lottery Draw? The IDDT Lottery READ MORE IDDT offer a comprehensive collection of FREE leaflets, including advice for people - and those caring for someone - with diabetes Publications READ MORE Our latest newsletters available to download Winter Newsletter and Type 2 & You READ MORE

Introducing IDDT – the InDependent Diabetes Trust.

Introducing IDDT

By introducingIDDT, Latest News

We are an organisation for people living with diabetes run by people living with diabetes. We recognise that when one person in a family lives with diabetes, this affects other family members and we offer support to partners and parents. We raise awareness of important issues for people with diabetes and provide information in non-medical language.

Read more…

A charity based in the UK listening to people with diabetes and their carers and supporting their needs. The Trust is run entirely by voluntary donations and we do not accept funding from the pharmaceutical industry in order to remain uninfluenced and independent.

The InDependent Diabetes Trust (IDDT) is a registered charity and was formed in 1994. We are concerned with listening to the needs of people who live with diabetes, understanding those needs and doing our utmost to offer help and support. We not only want to help those who actually have diabetes but also their carers – the husbands, wives, partners and parents, indeed, all of us who ‘live with diabetes’. We recognise that when one person in a family has diabetes, all other family members are affected to a greater or lesser extent and they all have views and needs which may be different from the person with diabetes, but nevertheless are important.

The Trust was set up to look at some of the day to day difficulties of living with diabetes, the worries, fears and concerns that perhaps we don’t talk about at the hospital clinic- the ones that many of us experience and understand because we actually live with diabetes. As a charity, IDDT has a Board of Trustees and all our Trustees either have diabetes or have family members with diabetes. So we all know first hand that while diabetes doesn’t rule our lives, it is an important part of them. It needs care and attention, it can be a nuisance and it is not without it’s problems!

Government confirms indefinite recognition of CE medical devices

By Latest News

The UK Government has confirmed that patients across the UK will continue to have access to the medical devices and in vitro diagnostic devices (IVDs) they rely on, from insulin pumps and replacement joints to diagnostic tests and surgical equipment. On 21 October 2026, the government confirmed that it will continue to accept CE marked medical devices on a long-term basis.

Click here for more details

Insulin pump therapy

By Latest News

This is an alternative to injecting insulin is to use continuous subcutaneous insulin infusion (CSII) with an insulin pump. This is where there is a continuous infusion of rapid /short-acting insulin delivered by a short cannula under the skin with boluses of insulin given to cover meals.

Click here for more details

NICE guidance on teplizumab

By Latest News

Teplizumab was licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in August 2025, to delay the onset of Stage 3 Type 1 diabetes for up to 3 years in adult and paediatric patients 8 years of age and older with Stage 2 Type 1 diabetes. NICE has now approved the use of teplizumab on the NHS for these people.

Click here for more details

GP practices in England are to be paid an average of £3,000 a year in bonuses to prescribe weight loss drugs to patients

By Latest News

The government is adding incentive payments of up to £3,000 to the GP contract starting in April but the payments will only apply to Mounjaro. This will be the first time weight loss drugs have been made part of the GP contract with £3,000 available for prescribing Mounjaro to the maximum number of eligible patients.

Click here for more details

MHRA issues strengthened warnings on acute pancreatitis,

By Latest News

…including necrotising and fatal cases for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and fatal pancreatitis. (Published 29th January 2026)

Click here for more details

Abbott Laboratories have issued with a field safety notice warning of a fault affecting certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose sensors

By Latest News

Abbott Laboratories, the manufacturer has discovered that some sensors could give inaccurate low glucose readings, which could lead to inappropriate treatment decisions and potentially serious harm among people with diabetes. The issue is limited to the FreeStyle Libre 3 and Libre 3 Plus sensors and Abbott stressed this issue does not apply to any other Libre sensors, apps or readers available in the UK.

Click here for more details

InDependent Diabetes Trust